Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Article - 21/02/2011 13724_de.jpg

    Hope for more effective brain tumour therapy

    Glioblastoma is the most common and most aggressive type of brain tumour in humans. It has a tendency to recur and it carries a bad prognosis. Intensive research into the molecular reaction chains involved in its pathogenesis has led to promising and effective treatment strategies.

    https://www.gesundheitsindustrie-bw.de/en/article/news/hope-for-more-effective-brain-tumour-therapy
  • Article - 07/02/2011 13564_de.jpg

    The discovery of the individual as business model

    The move towards personalised medicine has made considerable progress, in particular in the field of oncology, where it is leading to the close integration of diagnostics and therapy as well as to the development of profitable new business models, some of which have controversial exclusive legal claims.

    https://www.gesundheitsindustrie-bw.de/en/article/news/the-discovery-of-the-individual-as-business-model
  • Article - 29/04/2010 11236_de.jpg

    Cancer stem cells arise from tissue stem cells

    The Tlx transcription factor induces the transformation of neural stem cells into new nerve cells in the adult brain. Scientists at the German Cancer Research Centre in Heidelberg showed that the overproduction of Tlx and the silencing of the p53 tumour suppressor gene in mice stimulates the development of malignant brain tumours glioblastomas from brain stem cells.

    https://www.gesundheitsindustrie-bw.de/en/article/news/cancer-stem-cells-arise-from-tissue-stem-cells
  • Article - 25/02/2010 one bottle with Erbitux infusion of Merck

    Molecular marker for the treatment of lung cancer

    Whether the treatment of lung cancer with therapeutic antibodies is successful or not largely depends on the genetic makeup of the tumour. There is a need for reliable biomarkers that can predict patients’ response to treatment.

    https://www.gesundheitsindustrie-bw.de/en/article/news/molecular-marker-for-the-treatment-of-lung-cancer
  • Article - 25/01/2010 The photo shows a cross-section through a mutated fish larve eye. The cells are blue and the lens transparent. The cells behind the cells have a chaotic structure.

    The two sides of a cell

    Almost all cells are asymmetric – this is why for example the intestines, the brain and lungs function so well. Tumour diseases show why it is so important for a cell to have two different sides, a “head” and a “foot”. In cancer, genes that are responsible for the correct development of cell polarity are often defective. Dr. Felix Loosli from the Karlsruhe Institute of Technology investigates epithelial cells in the retina of the small Japanese…

    https://www.gesundheitsindustrie-bw.de/en/article/news/the-two-sides-of-a-cell
  • Press release - 24/11/2009 08652_de.jpg

    Three new collaborative research centres in Baden-Württemberg

    The German Research Foundation (DFG) is set to establish 17 new collaborative research centres (SFBs) on 1st January 2010. Ten of the new SFBs will focus on life science research projects, and will initially be funded for a period of four years with a total of 78 million euros in funding. One of the SFBs will be established at the University of Freiburg. Six of the 17 new SFBs are SFB/Transregio projects involving researchers from several German…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/three-new-collaborative-research-centres-in-baden-wuerttemberg
  • Article - 10/09/2009 09627_de.jpg

    Cadherins – keeping cells together is not their only purpose

    If they are absent everything goes wrong. Right from the development of the embryo the cell adhesion molecules of the cadherin superfamily ensure that cells are bound together while they are developing and when they become adult organisms. Cadherins fix tissue in place and give it shape and identity. But this is far from being all that they do. Dr. Dirk Junghans and his team at the Freiburg University Medical Centre have carried out experiments…

    https://www.gesundheitsindustrie-bw.de/en/article/news/cadherins-keeping-cells-together-is-not-their-only-purpose
  • Article - 23/07/2009 09223_de.jpg

    Making cancer cells commit suicide

    They divide and divide, and no natural border can stop them. Tumours such as the Ewing sarcoma, a bone cancer that occurs predominantly in teenagers, grow incessantly, making treatment difficult. A few years ago, Prof. Dr. Udo Kontny and his team from the University Hospital in Freiburg discovered a way to stop the growth of this particular tumour by activating a switch on the surface of cells which induces cellular death. Can physicians learn to…

    https://www.gesundheitsindustrie-bw.de/en/article/news/making-cancer-cells-commit-suicide
  • Article - 14/07/2009 Dr. Marcus Groettrup holding a test tube and pipette.

    Tiny particles are a weapon against tumours

    Prostate carcinoma is one of the most common malignant diseases claiming more than 84000 lives per year in the EU and the United States. In cooperation with the University of Constance the Thurgau Biotechnology Institute BITg is working on ways to remove prostate carcinomas and other tumours that are difficult to treat by using tiny particles made of biologically degradable polyester. Prof. Dr. Marcus Groettrup and his team of researchers have…

    https://www.gesundheitsindustrie-bw.de/en/article/news/tiny-particles-are-a-weapon-against-tumours
  • Article - 29/06/2009 Reconstruction of the CD44 protein structure which has numerous alternative variants.

    Alternative protein structures and breast cancer

    A single protein can have many variants. This variability is achieved by a process known as splicing which can introduce small modifications into the mRNA transcript of a gene. Prof. Dr. Elmar Stickeler from the University Womens Hospital in Freiburg found that some of these splice variants can also induce cancer. Stickeler and his team are investigating how splicing factors change their target molecules and how this leads to breast cancer. This…

    https://www.gesundheitsindustrie-bw.de/en/article/news/alternative-protein-structures-and-breast-cancer
  • Article - 22/06/2009 Microscopic detection of two melanoma cells (stained blue) in a sentinel lymph node – the new method now enables a quantitative statement to be made about the tumour load.

    New method enables the early and reliable detection of metastatic melanoma cells

    The presence of lymph node metastases has a considerable effect on the prognosis and therapy of patients with malignant melanomas. Therefore the histopathological examination of what are known as sentinel lymph nodes the first lymph nodes that metastasising cancer cells reach is of great importance. However the examination method has its technical limitations where very small metastases are concerned. Professor Dr. Anja Ulmer a dermatologist at…

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-method-enables-the-early-and-reliable-detection-of-metastatic-melanoma-cells
  • Press release - 22/06/2009 Green fluorescent cells - on the left with cell extensions, on the right rather rounded.

    New important triggers for the migration of cancer cells

    Embryonic cells and metastasising cancer cells are able to migrate and intrude into other tissues. Investigations of frog embryos have now provided scientists at the Karlsruhe Institute of Technology with the information that a well-known protein, cadherin-11, triggers cell migration. This glycoprotein is also responsible for the defective behaviour of cells that results in prostate cancer and arthritis.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-important-triggers-for-the-migration-of-cancer-cells
  • Press release - 10/06/2009 08818_de.jpg

    6.56 million euros for first full-body PET-MRI prototype

    The Joint Science Conference in Bonn has announced that the University of Tübingen will receive 6.56 million euros for the purchase of an entirely new multimodal full-body tomography system for the diagnosis of cancer. The new full-body PET-MRI combines positron emission tomography PET with magnetic resonance imaging MRI in one device.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/6-56-million-euros-for-first-full-body-pet-mri-prototype
  • Article - 11/05/2009 The cancer stem cell (CSC) hypothesis

    Metastasis-inducing cancer stem cells

    Just a small subpopulation of cancer cells namely metastasis-inducing cancer stem cells MICs is potentially responsible for the formation of distant malignant tumour metastases. The characterisation of MICs and the clarification of mechanisms that lead to their reactivation from a dormant state opens up new strategies for the development of new effective therapies against metastasising tumours.

    https://www.gesundheitsindustrie-bw.de/en/article/news/metastasis-inducing-cancer-stem-cells
  • Article - 20/04/2009 Biophysical data of the ND:YAG MY40 laser. The figure shows important laser parameters and tissue determinants. Of key importance is the low lung density of 0,15 g/ccm, 80% water content and strong shrinking capacity as a result of the air contained in the alveoles.

    Non-invasive laser technology for the treatment of malignant tumours

    The Department of Thoracic Surgery at Constance Hospital has since March 2009 been using an innovative laser scalpel for removing metastases of malignant tumours from the lung. This will open up numerous new possibilities which at the moment are unfortunately not fully exploited at all hospitals due to lack of knowledge.

    https://www.gesundheitsindustrie-bw.de/en/article/news/non-invasive-laser-technology-for-the-treatment-of-malignant-tumours
  • Article - 20/04/2009 08446_de.jpg

    Biomarkers for the identification of metastases

    Prof. Dr. Heike Allgayer a surgeon and molecular biologist from Heidelberg is investigating the molecular processes of the formation of tumour metastases. A major objective of her research is to find specific biomarkers that enable the early identification of metastases and to monitor the outcome of therapy. She has already received numerous prizes for her achievements.

    https://www.gesundheitsindustrie-bw.de/en/article/news/biomarkers-for-the-identification-of-metastases
  • Article - 07/04/2009 08360_de.jpg

    All-rounders that export cancer

    Migrating stem cells have been the focus of attention for some years now opening up potential new strategies for cancer research and therapy. Professor Dr. Thomas Brabletz and his team at the University Medical Centre in Freiburg are working on these stem cells that have an ability to generate new tumours anywhere in the body.

    https://www.gesundheitsindustrie-bw.de/en/article/news/all-rounders-that-export-cancer
  • Article - 18/02/2009 Portrait of Prof. Andreas Trumpp

    Dormant stem cells can be awakened with interferon alpha

    With a number of new papers published in renowned scientific journals Prof. Dr. Andreas Trumpp has been able to further cement his outstanding reputation as one of the world leaders in stem cell research. Trumpp who has been professor and head of the Department of Cell Biology at the German Cancer Research Centre DKFZ since summer 2008 also became head of the newly founded Heidelberg Institute for Stem Cell Technology and Experimental Medicine…

    https://www.gesundheitsindustrie-bw.de/en/article/news/dormant-stem-cells-can-be-awakened-with-interferon-alpha
  • Article - 02/02/2009

    CureVac enters premier biotech league with new cancer vaccine

    At present active immunotherapy seems to produce the best results in the treatment of cancer. The Tübingen-based biotech company CureVac is now hoping to achieve a breakthrough in cancer therapy with a worldwide unique vaccine. The first clinical trials have recently commenced.

    https://www.gesundheitsindustrie-bw.de/en/article/news/curevac-enters-premier-biotech-league-with-new-cancer-vaccine
  • Article - 11/12/2008

    New drug that targets metastasing breast cancer in clinical phase III trial

    Protein kinases are a major focus of modern cancer research. Since it has become known that these enzymes play a role in the development of tumours, researchers around the world are concentrating on finding drugs to inhibit overactive protein kinases and prevent cancer cells from growing. One of these active substances is currently being tested at the Tumour Biology Centre in Freiburg as part of a worldwide phase III clinical trial.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-drug-that-targets-metastasing-breast-cancer-in-clinical-phase-iii-trial
  • Press release - 20/10/2008

    Ultra fast magnetic resonance imaging

    The European Research Council is to fund a project at the University Hospital of Freiburg on the development of ultra fast magnetic resonance imaging for applications in the fields of neurology the neurosciences and oncology.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/ultra-fast-magnetic-resonance-imaging
  • Article - 02/08/2008

    Cellular Decision on the Computer

    Scientists of the Division of Theoretical Bioinformatics at the German Cancer Research Center DKFZ in Heidelberg have simulated on the computer how cells decide whether or not to migrate. The method forges new paths in cancer medicine.

    https://www.gesundheitsindustrie-bw.de/en/article/news/cellular-decision-on-the-computer
  • Press release - 04/07/2008

    Bracco Imaging: specialist in diagnostic imaging

    In future small bubbles will allow the identification of pathological alterations at a very early stage. Molecular imaging methods developed by Bracco Imaging S.p.A. use a new ultrasound contrast agent. The German subsidiary of the company Bracco Imaging Deutschland GmbH based in Constance develops and sells contrast agents.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/bracco-imaging-specialist-in-diagnostic-imaging
  • Article - 02/07/2008

    The cancer cells' sweet tooth might be their death sentence

    Cancer cells are dangerous foodies. They metabolise far greater amounts of sugar than healthy cells. Nuclear medicine experts make use of cancer cells craving for sugar since the advent of modern positron emission tomography PET. This has led to an improvement in the quality of cancer treatment.

    https://www.gesundheitsindustrie-bw.de/en/article/news/the-cancer-cells-sweet-tooth-might-be-their-death-sentence
  • Article - 01/05/2008

    Peter Öhlschläger - New strategies for the treatment of cancer

    Professor Peter Öhlschläger established his major scientific interests very early on. During his degree thesis at the German Cancer Research Centre DKFZ in Heidelberg the immunologist succeeded in combining his two major interests namely virology and cancer. Öhlschläger is now junior professor at the University of Constance and mainly deals with the development of therapeutic cancer vaccines.

    https://www.gesundheitsindustrie-bw.de/en/article/news/peter-hlschlaeger-new-strategies-for-the-treatment-of-cancer

Page 3 / 4

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • 2
  • 3
  • 4
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2023
Website address: https://www.gesundheitsindustrie-bw.de/en/search